Секвенирование "нового поколения" (NGS): применение для молекулярно-генетических исследований в онкологии

Бесплатный доступ

Секвенирование «нового поколения» в качестве комплексного высокопроизводительного диагностического и прогностического молекулярно-генетического метода активно внедряется в практическую медицину. В настоящее время доступны как полногеномные и полноэкзомные исследования, так и различные таргетные панели для NGS. В обзоре рассмотрены основные принципы и технологии высокопроизводительного секвенирования для использующихся в настоящее время коммерческих платформ (подготовка библиотек, секвенирование и обработка полученных данных), а также применение данного метода в клинической онкологии для выявления герминальных и соматических мутаций в таргетных генах и поиска новых генетических вариантов, ассоциированных с онкологическими заболеваниями.

Еще

Секвенирование "нового поколения" (ngs), диагностический и прогностический молекулярно-генетический метод, герминальные мутации, соматические мутации персонализированная медицина

Короткий адрес: https://sciup.org/14955510

IDR: 14955510

Next-generation sequencing (NGS): application in molecular genetic studies in oncology

Next-generation sequencing as a complex high-throughput diagnosis and prognosis molecular genetic method is actively implemented in practical medicine. Whole-genome sequencing, whole-exome sequencing and different targeted region panels for NGS are available now. In this review fundamental principles and technologies of high-throughput sequencing for the currently used commercial platforms (library preparation, sequencing and obtained data processing) are considered, as well as the application of this method in clinical oncology to identify germline and somatic mutations in the targeted genes and search for new cancer associated genetic variants.

Еще

Список литературы Секвенирование "нового поколения" (NGS): применение для молекулярно-генетических исследований в онкологии

  • Иванов М.В., Новикова Е.И., Баранова А.В. и др. Опыт использования высокопроизводительного секвенирования (NGS) для подбора таргетной терапии при немелкоклеточном раке легкого: преимущества и ограничения.//Международный ежеквартальный научно-практический журнал по онкологии "Злокачественные опухоли". Москва. 2015. №4. С.310-311.
  • Немцова М.В., Танас А.С., Алексеева Е.А. и др. Соматические и герминальные мутации при раке желудка.//Молекулярная медицина. 2015. №4. С.28-34.
  • Снигирева Г.П., Агаджанян А.В., Новицкая Н.Н. и др. Роль молекулярно-генетического исследования при раке молочной железы.//Международный ежеквартальный научнопрактический журнал по онкологии "Злокачественные опухоли". Москва. 2014. №3. С.213.
  • Berger M.F., Lawrence M S., Demichelis F. et al. The genomic complexity of primary human prostate cancer.//Nature. 2011. V. 470. N. 7333. P. 214-220.
  • Berglund E C., Kiialainen A., Syvä nen, A C. Next-generation sequencing technologies and applications for human genetic history and forensics.//Investig. Genet., 2011. V. 2. P. 23.
  • Brennan C W., Verhaak R G., McKenna A. et al. The somatic genomic landscape of glioblastoma.//Cell. 2014. V. 157. N. 3. P. 753.
  • Chapman P.B., Hauschild A., Robert C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.//N. Engl. J. Med. 2011. V. 364. N. 26. P. 2507-2516.
  • Cronin M., Ross J S. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.//Biomark Med. 2011. V. 5. N. 3. P. 293-305.
  • Desai A N., Jere A. Next-generation sequencing: ready for the clinics?//Clin Genet. 2012. V. 81. N. 6. P. 503-510.
  • Diaz L.A. Jr., Sausen M., Fisher G A. et al. Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA.//Oncotarget. 2013. V. 4. N. 10. P. 1856-1857.
  • Diaz, L A. Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA.//J. Clin. Oncol. 2014. V. 32. N. 6. P. 579-586.
  • Forshew T., Murtaza M., Parkinson C. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.//Sci Transl Med. 2012. V. 4. N. 136:136ra68.
  • Gudmundsdottir K., Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.//Oncogene. 2006. V. 25. N. 43. P. 5864-5874.
  • Gui Y., Guo G., Huang Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.//Nat Genet. 2011. V. 43. N. 9. P. 875-878.
  • Guo G., Gui Y., Gao S. et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma.//Nat Genet. 2011. V. 44. N. 1. P. 17-19.
  • Helleday T., Petermann E., Lundin C. et al. DNA repair pathways as targets for cancer therapy.//Nature Reviews Cancer. 2008. V. 8. N. 3. Р. 193-204.
  • Keller A., Harz C., Matzas M. et al. Identification of novel SNPs in glioblastoma using targeted resequencing.//PLoS One. 2011. V. 6. N. 6: e18158.
  • Ku C S., Wu M., Cooper D N. et al. Technological advances in DNA sequence enrichment and sequencing for germline genetic diagnosis.//Expert Rev Mol Diagn. 2012. V. 12. N. 2. P. 159-173.
  • Leary R J., Sausen M., Kinde I. et al. (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing.//Sci. Transl. Med. 2012. V. 4. N. 162: 162ra154.
  • Lev-Ari A. Sunitinib brings Adult acute lymphoblastic leukemia (ALL) to Remission-RNA Sequencing-FLT3 Receptor Blockade. 2012.
  • Ley T J., Mardis E R., Ding L. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.//Nature. 2008. V. 456. N. 7218. P. 66-72.
  • Marchetti A., Del G M., Filice G. et al. Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.//PLoS One. 2012. V. 7: e42164.
  • Mardis E R., Ding L., Dooling D J. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome.//N Engl J Med. 2009. V. 361. N. 11. P. 1058-1066.
  • Mardis E R. Applying next-generation sequencing to pancreatic cancer treatment.//Nat Rev Gastroenterol Hepatol. 2012. V. 9. N. 8. P. 477-486.
  • Meldrum C., Doyle MA., Tothill R W. Next-generation sequencing for cancer diagnostics: a practical perspective.//Clin Biochem Rev. 2011. V. 32. N. 4. P. 177-195.
  • Mok T S., Wu Y L., Thongprasert S. et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma.//N. Engl. J. Med. 2009. V. 361. P. 947-957.
  • Murtaza M., Dawson S J., Tsui D W. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.//Nature. 2013. V. 497. N. 7447. P. 108-112.
  • Narod S.A., Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond.//Nat Rev Cancer. 2004. V. 4. N. 9. P. 665-676.
  • Ozcelik H., Shi X., Chang M.C. et al. Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer.//J Mol Diagn. 2012. V. 14. N. 5. P. 467-475.
  • Pleasance E D., Cheetham K., Stephens P J. et al. A comprehensive catalogue of somatic mutations from a human cancer genome.//Nature. 2010. V. 463. N. 7278. P. 191-196.
  • Puente X S., Pinyol M., Quesada V. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.//Nature. 2011. V. 475. N. 7354. P. 101-105.
  • Quail M A., Smith M., Coupland P. et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers.//BMC Genomics. 2012. V. 13. P. 341.
  • Rizzo J M., Buck M J. Key principles and clinical applications of “next-generation” DNA sequencing.//Cancer Prev Res (Phila). 2012. V. 5. N. 7. P. 887-900.
  • Ross J S., Cronin M. Whole cancer genome sequencing by next-generation methods.//Am J Clin Pathol. 2011. V. 136. N. 4. P. 527-539.
  • Roychowdhury S., Iyer M.K., Robinson D R et al. Personalized oncology through integrative high-throughput sequencing: a pilot study.//Sci Transl Med. 2011. V. 3. N. 111: 111ra121.
  • Sanger F., Nicklen S., Coulson A. DNA sequencing with chain-terminating inhibitors//Proceedings of the National Academy of Sciences USA. 1977. V. 74. N. 12. P. 5463-5467.
  • Walsh T., Casadei S., Coats K.H. et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.//JAMA. 2006. V. 295. N. 12. P. 1379-1388.
  • Walsh T., Lee M.K., Casadei S. et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.//Proc Natl Acad Sci U S A. 2010. V. 107. N. 28. P. 12629-12633.
  • Welch J S., Westervelt P., Ding L. et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.//JAMA. 2011. V. 305. N. 15. P. 1577-1584.
Еще